CD38 and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, longstanding observations have revealed that CML patients at diagnosis contain both BCR::ABL1+ LSCs vs. BCR::ABL1- HSC within the Lin-CD34+CD38-/low immunophenotypic compartment, and BCR::ABL1+ LSCs suppress residual normal HSCs (Chen et al., 2023; Coulombel et al., 1983).